Inside STAT: A major drug maker is paying doctors again, after halting the practice

The drug maker GlaxoSmithKline did something unexpected a few years back — it pledged that it would no longer pay doctors to promote its medicines, as so many other drug makers do. It was a bold move; it was also, apparently, not permanent. GSK now says it will largely reverse course because the earlier shift put the company at a competitive disadvantage. In a new column, STAT's Ed Silverman says that decision is unfortunate, and has real consequences for patients. Read here.